Can Lynparza Hold On As PARP Inhibitors Enter First-Line Prostate Cancer Market?
Executive Summary
AstraZeneca, Pfizer and Johnson & Johnson are presenting Phase III data for PARP inhibitors combined with anti-androgen drugs in first-line mCRPC, a potential blockbuster opportunity.
You may also be interested in...
Pfizer Scores Broad Label For Talzenna/Xtandi In Valuable First-Line Prostate Cancer Indication
The FDA approved the combination for patients with HRR gene-mutated disease, giving it a broader label than the BRCA-mutation label that AstraZeneca/Merck got for Lynparza/Zytiga.
AstraZeneca’s Lynparza Adds Narrow Prostate Cancer Indication
AstraZeneca had hoped data from Phase III PROpel would lead to an all-comers indication in first-line, metastatic castration-resistant prostate cancer, but new indication is limited to BRCA mutations.
Pfizer/Astellas Take Off On New Xtandi Expansion With EMBARK Data
Data from the Phase III EMBARK study showed a significant improvement for the drug both in combination with leuprolide and as a monotherapy in reducing risk of metastasis or death in nmHSPC.